Efficacy of bromocriptine administration for selective pituitary resistance to thyroid hormone
Related Experiment Video
Updated: Nov 8, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
T Ohzeki1, K Hanaki, H Motozumi
1Department of Pediatrics, Faculty of Medicine, Tottori University, Yonago, Japan.
Abstract:
The relation between thyroid-stimulating hormone (TSH) and triiodothyronine (T3) was evaluated in a girl with the selective pituitary type of thyroid hormone resistance for more than 7 years to clarify whether bromocriptine was an effective treatment or not. Levels of T3 (before: 2.44 +/- 0.64 nmol/l, mean +/- SD) and TSH (4.81 +/- 2.52 mU/l) were significantly decreased during therapy (T3: 2.15 +/- 0.44 nmol/l; TSH: 1.59 +/- 0.78 mU/l). T3 x TSH, calculated as one of the indices of pituitary resistance, on bromocriptine therapy (3.229 +/- 1.255 mU/l x nmol/l) was significantly (p < 0.005) smaller than the product before the administration (11.298 +/- 5.891 mU/l x nmol/l). The results suggest that bromocriptine should be one of the agents initially considered for the treatment of pituitary resistance to thyroid hormone.
Related Concept Videos
Hypothyroidism II: Pathophysiology
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Hyperthyroidism II: Pathophysiology
Dose-Response Relationship: Potency and Efficacy
Hyperthyroidism I: Introduction
